Drug Type Antibody |
Synonyms- |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | Canada | 12 Oct 2022 | |
Head and Neck Neoplasms | Preclinical | Canada | 12 Oct 2022 | |
Lung Cancer | Preclinical | Canada | 12 Oct 2022 | |
Pancreatic Cancer | Preclinical | Canada | 12 Oct 2022 |